Log in

NASDAQ:MNOVMediciNova Stock Price, Forecast & News

$5.65
-0.14 (-2.42 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$5.36
Now: $5.65
$5.69
50-Day Range
$5.13
MA: $5.49
$6.36
52-Week Range
$2.79
Now: $5.65
$10.84
Volume352,154 shs
Average Volume172,177 shs
Market Capitalization$249.00 million
P/E RatioN/A
Dividend YieldN/A
Beta1.72
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective ß2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company was founded in 2000 and is headquartered in La Jolla, California.
Read More
MediciNova logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.24 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MNOV
CUSIPN/A
Phone858-373-1500

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.71 per share

Profitability

Net Income$-12,940,000.00

Miscellaneous

Employees9
Market Cap$249.00 million
Next Earnings Date7/23/2020 (Estimated)
OptionableOptionable

Receive MNOV News and Ratings via Email

Sign-up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.

MediciNova (NASDAQ:MNOV) Frequently Asked Questions

How has MediciNova's stock been impacted by COVID-19 (Coronavirus)?

MediciNova's stock was trading at $3.29 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MNOV shares have increased by 71.7% and is now trading at $5.65. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of MediciNova?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MediciNova.

When is MediciNova's next earnings date?

MediciNova is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for MediciNova.

How were MediciNova's earnings last quarter?

MediciNova, Inc. (NASDAQ:MNOV) posted its earnings results on Thursday, April, 23rd. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.08) by $0.02. View MediciNova's earnings history.

What price target have analysts set for MNOV?

1 analysts have issued 12-month price objectives for MediciNova's stock. Their forecasts range from $11.00 to $11.00. On average, they anticipate MediciNova's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 94.7% from the stock's current price. View analysts' price targets for MediciNova.

Has MediciNova been receiving favorable news coverage?

Headlines about MNOV stock have trended negative this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. MediciNova earned a media sentiment score of -2.8 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 7.0 out of 10, indicating that recent news coverage is likely to have an impact on the stock's share price in the next few days. View the latest news about MediciNova.

Who are some of MediciNova's key competitors?

What other stocks do shareholders of MediciNova own?

Who are MediciNova's key executives?

MediciNova's management team includes the following people:
  • Dr. Yuichi Iwaki, Co-Founder, Pres, CEO & Exec. Director (Age 69)
  • Mr. Masatsune Okajima, Head of Japanese Office & VP (Age 51)
  • Dr. Kazuko Matsuda M.P.H., M.D., Ph.D., MPH, Chief Medical Officer (Age 53)
  • Ms. Carla Reyes, Chief Financial Officer (Age 47)
  • Mr. John O'Neil CPA, Controller

What is MediciNova's stock symbol?

MediciNova trades on the NASDAQ under the ticker symbol "MNOV."

How do I buy shares of MediciNova?

Shares of MNOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is MediciNova's stock price today?

One share of MNOV stock can currently be purchased for approximately $5.65.

How big of a company is MediciNova?

MediciNova has a market capitalization of $249.00 million. MediciNova employs 9 workers across the globe.

What is MediciNova's official website?

The official website for MediciNova is medicinova.com.

How can I contact MediciNova?

MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The biopharmaceutical company can be reached via phone at 858-373-1500 or via email at [email protected]

This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.